Differentiating between low-grade gliomas (LGGs) of astrocytic and oligodendroglial origin remains a major challenge in neurooncology. Here the authors analyzed The Cancer Genome Atlas (TCGA) profiles of LGGs with the goal of identifying distinct molecular characteristics that would afford accurate and reliable discrimination of astrocytic and oligodendroglial tumors. They found that 1) oligodendrogliomas are more likely to exhibit the gliomaCpG island methylator phenotype (G-CIMP), relative to low-grade astrocytomas; 2) relative to oligodendrogliomas, low-grade astrocytomas exhibit a higher expression of genes related to mitosis, replication, and inflammation; and 3) low-grade astrocytic tumors harbor microRNA profiles similar to those previously described for glioblastoma tumors. Orthogonal intersection of these molecular characteristics with existing molecular markers, such as IDH1 mutation, TP53 mutation, and 1p19q status, should facilitate accurate and reliable pathological diagnosis of LGGs.
D ifferentiating between
LGGs of astrocytic and oligodendroglial origin remains a major challenge in neurooncology. 8, 23, 28 Overcoming this challenge is paramount. Astrocytic and oligodendroglial tumors exhibit distinct natural histories, biologies, and therapeutic responses. 14, 33 As such, our ability to appropriately care for patients afflicted with LGGs and advance the standard of care greatly depends on accurate pathological diagnosis.
It is increasingly apparent that histological features are insufficient for consistently discriminating between the astrocytic and oligocytic LGG (Fig. 1) . 8, 25 There is a general consensus in terms of the need for molecular tools in this regard. 24, 30 While great strides have been made toward the development of these tools with the discovery of TP53 mutations and 1p19q deletions, reliable molecular diagnosis remains elusive for the 30%-50% of LGGs that do not harbor these molecular markers. 11, 18 We propose that the discrimination of astrocytic and oligocytic LGGs can be facilitated by comprehensive molecular analysis of these tumors. To this end, we analyzed the publicly available multiplatform molecular analysis of
LGGs from TCGA. 
Methods

Determination of G-CIMP Status
Methylation data related to glioblastoma and LGG were downloaded from TCGA data portal. The Level II data have been preprocessed and normalized per probe set by TCGA working group. Using the methods described by Noushmehr et al., 20 we identified the top 1427 probes whose DNA methylation beta values varied most across the glioblastoma and LGG samples. The glioblastoma and LGG data sets were grouped and classified by k-medians clustering (number of clusters 3) of the selected probe sets. All clustering of the data and construction of the heatmaps were performed using the TM4 MultiExperiment Viewer (version 4.7.4, Dana-Farber Cancer Institute). 27 
Determination of TCGA Subtype
Level III mRNA expression data were obtained from TCGA data portal for 27 LGG and 603 GBM specimens. Level III data consisted of expression calls for genes per sample following processing and normalization including log2 transformation of the gene expression levels. Data from the LGG and GBM samples were compiled into a single data set, and relative gene expression values were calculated by subtracting from the gene estimate the mean expression values across patients and then dividing the difference by the standard deviation across all patients. Using the 840 gene signature reported by Verhaak et al., 32 we classified the tumors into proneural, neural, classical, and mesenchymal subtypes by k-medians clustering (number of clusters 4).
Differential Gene Expression Analysis
Level III mRNA expression data from Agilent Technologies G4502A-07 microarrays were obtained from The Cancer Genome Atlas expression profiles of low-grade gliomas TCGA data portal. The mean fold change analysis between the low-grade astrocytomas and oligodendrogliomas was performed on all genes in the full 17813 gene data set. Genes that demonstrated mean differential expression of at least 2-fold were kept as interesting genes for further analysis. Gene lists of interest were uploaded and analyzed using the online gene ontology tool DAVID 6.7 (National Institute of Allergy and Infectious Diseases, NIH, http://david.abcc.ncifcrf.gov/). 9, 10 Level III miRNA expression data and their corresponding clinical data from 47 LGG samples were downloaded from TCGA data portal. The miRNA quantification data from each sample were combined into a single data set, and then mean fold change values for each gene were calculated by comparing astrocytomas with oligodendrogliomas. The miRNAs that demonstrated a mean fold change of at least 2 were kept as potentially interesting miRNAs for further analysis. The miRNAs were organized according to unsupervised hierarchical clustering, and the samples were grouped according to histological diagnosis.
Results
The G-CIMP Status
The G-CIMP status was determined for 24 LGGs (composing 11 oligodendrogliomas, 8 oligoastrocytomas, and 5 astrocytomas), 294 GBMs, and 2 matched normal specimens. Seventeen (70.8%) of the 24 LGGs were G-CIMP-positive tumors, compared with only 8.5% G-CIMP positivity among the 294 GBMs analyzed (Fig.  2 left) . All oligodendrogliomas (11 of 11) exhibited G-CIMP positivity (Fig. 2 right) . Only 1 of 5 astrocytomas was G-CIMP positive, whereas the distribution among oligoastrocytomas was more evenly divided, with 6 of 9 being G-CIMP positive. Both matched normal specimens were negative for the hypermethylation phenotype.
Analysis of mRNA
Twenty-seven LGG specimens were classified according to TCGA subtype by the expression pattern of the 840 gene signature defined by Verhaak et al. 32 The LGGs analyzed included 8 oligodendrogliomas (4 WHO Grade II, 4 WHO Grade III), 9 oligoastrocytomas (2 WHO Grade II, 7 WHO Grade III), and 10 astrocytomas (1 WHO Grade II, 9 WHO Grade III). All but one of the characterized LGGs had gene expression characteristics of the proneural glioma subtype (Fig. 3 left) . The lone exception was a WHO Grade II oligodendroglioma in a patient whose tumor's molecular characteristics were consistent with the mesenchymal subtype. Notably, this lone patient with the mesenchymal oligodendroglioma died within 2 years of the surgical diagnosis, demonstrating a more aggressive course than is typically seen in oligodendroglioma tumors. Differential gene expression analysis was then performed comparing oligodendrogliomas with astrocytomas ( Fig. 3 right) . The oligoastrocytomas were not included in this analysis since they represent a less descript subtype with overlapping histological components of the other 2 tumor types. Using a 2-fold mean differential expression cutoff, 338 genes were found to be upregulated and 283 genes were downregulated in the astrocytomas relative to the oligodendrogliomas. Gene ontology analysis of the 338 upregulated genes yielded gene ontology terms related primarily to mitotic functions and the inflammatory response, for example, mitosis, cell cycle phase, immune response, and inflammatory response ( Table 1 ). The most significant cluster had an enrichment score of 8.64 and contained 54 of the 338 upregulated genes, many of which were mRNAs coding for inflammatory cell receptors, ligands, and major histocompatibility complexes. The cluster enrichment score for mitotic genes was 6.37, and this cluster consisted of 61 of the 338 upregulated genes. 
Analysis of miRNA
We also compared miRNA expression differences between 23 oligodendrogliomas (12 WHO Grade II, 11 WHO Grade III) and 24 astrocytomas (2 WHO Grade II, 22 WHO Grade III) as obtained from TCGA microarray data (Fig. 4) . Nine miRNAs were upregulated and 28 were downregulated more than 2-fold within the astrocytomas relative to the oligodendrogliomas ( Table 2 ). The upregulated list included miRNAs known to be upregulated in GBMs as well as a variety of nonneural tumors such as miR-21.
5 Downregulated miRNAs included those associated with neuronal differentiation, which are LGG samples combined with 294 GBM samples revealing the G-CIMP status after k-medians clustering (number of clusters 3) of the sample order. The level of DNA methylation (beta value) for each probe in each sample is represented by a color scale, with red indicating higher levels of methylation and green showing lower levels. Each sample is color labeled as described in the key for its tumor histology type (LGG vs GBM). Right: Heatmap of the 24 LGG samples clustered alone by k-medians clustering (number of clusters 3) revealing the G-CIMP status. Again, each sample is color labeled as described in the key for its tumor histology type (oligodendroglioma vs astrocytoma vs oligoastrocytoma). known to be downregulated in higher-grade glial tumors such as miR-124 and miR-128. 13 
Discussion
Diagnostic uncertainty in discriminating between
LGGs of oligocytic and astrocytic lineage remains a major challenge in neurooncology. Here, we analyzed TCGA data set in search of molecular biomarkers that could facilitate discrimination. The key findings of our study are as follows: 1) oligodendrogliomas are more likely to exhibit the G-CIMP phenotype relative to low-grade astrocytomas; 2) relative to oligodendrogliomas, low-grade astrocytomas exhibit a higher expression of genes related to mitosis, replication, and inflammation; and 3) low-grade astrocytic tumors harbor miRNA profiles similar to those previously described for glioblastoma tumors. Notably, such miRNA profiles were not observed in oligodendrogliomas. These molecular features may augment conventional histopathology in discriminating oligodendrogliomas from low-grade astrocytomas.
The G-CIMP phenotype was initially described by Noushmehr et al. 20 as a pattern of epigenetic modification that is found in a subset of glioblastomas. These tumors exhibit increased methylation of cytosine in CpG islands that are often found in the promoter regions of transcribed genes. 3 It is thought that promoter methylation silences critical genes that mediate glioblastoma aggressiveness and therapeutic resistance. Consequently, G-CIMP-positive glioblastomas have a better prognosis than glioblastomas without the G-CIMP phenotype. 20 Our observation that oligodendrogliomas are more likely to harbor the G-CIMP phenotype is largely consistent with the more favorable prognosis of this LGG relative to low-grade astrocytic tumors. Five-year survival for patients with astrocytic LGGs is 56% compared with 74% in those with predominantly oligodendritic gliomas. 33 Some oligodendrogliomas with 1p/19q deletions are still slower growing tumors with even more indolent courses. 25 The increased expression of mRNAs related to mitosis and inflammation in low-grade astrocytomas relative to ol- igodendrogliomas is also consistent with the more aggressive clinical course of the astrocytomas. 29, 33 The increased expression of mRNAs related to mitosis probably mirrors increased rates of tumor proliferation. 8 Increased expression of inflammatory cytokines in glioblastoma specimens has been associated with worsened overall survival. 31, 34, 36 Emerging evidence suggests that the presence of inflammatory cytokines may enhance glioblastoma growth as well as suppress apoptotic and senescent processes within glioblastomas. 6, 36 The inflammatory markers upregulated in astrocytomas in the current analysis may reflect the increased number of microglia in astrocytic gliomas relative to oligodendrogliomas 7, 26 or the inherent expression of cytokines by astrocytic gliomas. 12, 19, 35, 36 Aberrant miRNA expression is a universal theme during carcinogenesis. 16 Moreover, the pattern of miRNA expression often marks the lineage of origin with regard to the tumor. 15, 17 In this context, it is gratifying that we uncovered distinct miRNA profiles in astrocytic and oligodendrocytic
LGGs. Several of the miRNAs we found to be expressed at higher levels in the astrocytomas as compared with the oligodendrogliomas have been previously described as key contributors to glioblastoma formation, including miR-21.
2,22 Conversely, many of the miRNAs downregulated in astrocytomas relative to oligodendrogliomas have been shown to be required in maintaining astrocytic differentiation, including miR-124 4 and miR-128.
21
Conclusions
Oligodendrogliomas and low-grade astrocytomas exhibit distinctly different molecular characteristics including G-CIMP status, mRNA expression, and miRNA profiles. Incorporation of these molecular platforms with existing molecular markers, such as IDH1 mutation, TP53 mutation, and 1p19q status, should facilitate accurate and reliable pathological diagnosis of LGGs.
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